NZ511113A - Adjuvant systems containing an immunostimulant absorbed on to a metal salt particle and vaccines thereof - Google Patents

Adjuvant systems containing an immunostimulant absorbed on to a metal salt particle and vaccines thereof

Info

Publication number
NZ511113A
NZ511113A NZ511113A NZ51111399A NZ511113A NZ 511113 A NZ511113 A NZ 511113A NZ 511113 A NZ511113 A NZ 511113A NZ 51111399 A NZ51111399 A NZ 51111399A NZ 511113 A NZ511113 A NZ 511113A
Authority
NZ
New Zealand
Prior art keywords
immunostimulant
salt particle
vaccines
absorbed
metal salt
Prior art date
Application number
NZ511113A
Other languages
English (en)
Inventor
Nathalie Garcon
Original Assignee
Smithkline Beecham Biolog S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ511113(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9822703.6A external-priority patent/GB9822703D0/en
Priority claimed from GBGB9822712.7A external-priority patent/GB9822712D0/en
Priority claimed from GBGB9822709.3A external-priority patent/GB9822709D0/en
Application filed by Smithkline Beecham Biolog S filed Critical Smithkline Beecham Biolog S
Publication of NZ511113A publication Critical patent/NZ511113A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ511113A 1998-10-16 1999-10-08 Adjuvant systems containing an immunostimulant absorbed on to a metal salt particle and vaccines thereof NZ511113A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9822703.6A GB9822703D0 (en) 1998-10-16 1998-10-16 Vaccine
GBGB9822712.7A GB9822712D0 (en) 1998-10-16 1998-10-16 Vaccine
GBGB9822709.3A GB9822709D0 (en) 1998-10-16 1998-10-16 Vaccine
PCT/EP1999/007764 WO2000023105A2 (en) 1998-10-16 1999-10-08 Adjuvant systems and vaccines

Publications (1)

Publication Number Publication Date
NZ511113A true NZ511113A (en) 2002-09-27

Family

ID=27269522

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ511113A NZ511113A (en) 1998-10-16 1999-10-08 Adjuvant systems containing an immunostimulant absorbed on to a metal salt particle and vaccines thereof

Country Status (31)

Country Link
US (3) US7357936B1 (OSRAM)
EP (5) EP2266604A3 (OSRAM)
JP (3) JP2003519084A (OSRAM)
KR (1) KR100629028B1 (OSRAM)
CN (3) CN100558401C (OSRAM)
AR (1) AR020836A1 (OSRAM)
AT (1) ATE357252T1 (OSRAM)
AU (1) AU750587B2 (OSRAM)
BR (1) BRPI9915545B8 (OSRAM)
CA (2) CA2773698C (OSRAM)
CO (1) CO5210894A1 (OSRAM)
CY (2) CY1106596T1 (OSRAM)
CZ (1) CZ301212B6 (OSRAM)
DE (2) DE69935606T9 (OSRAM)
DK (1) DK1126876T3 (OSRAM)
ES (1) ES2284287T3 (OSRAM)
FR (1) FR07C0064I1 (OSRAM)
HK (1) HK1038695B (OSRAM)
HU (2) HU228473B1 (OSRAM)
IL (2) IL142395A0 (OSRAM)
LU (1) LU91389I2 (OSRAM)
MY (1) MY124689A (OSRAM)
NL (1) NL300311I2 (OSRAM)
NO (1) NO336250B1 (OSRAM)
NZ (1) NZ511113A (OSRAM)
PL (1) PL201482B1 (OSRAM)
PT (1) PT1126876E (OSRAM)
SI (1) SI1126876T1 (OSRAM)
TR (1) TR200101055T2 (OSRAM)
TW (1) TW586936B (OSRAM)
WO (1) WO2000023105A2 (OSRAM)

Families Citing this family (269)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK0909323T3 (da) 1996-01-04 2007-05-21 Novartis Vaccines & Diagnostic Helicobacter pylori-bakterioferritin
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2328894A1 (en) 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity
IL142395A0 (en) * 1998-10-16 2002-03-10 Smithkline Beecham Biolog Adjuvant systems and vaccines
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
WO2001000232A2 (en) * 1999-06-29 2001-01-04 Smithkline Beecham Biologicals S.A. Use of cpg as an adjuvant for hiv vaccine
GB9915204D0 (en) * 1999-06-29 1999-09-01 Smithkline Beecham Biolog Vaccine
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0025170D0 (en) * 2000-10-13 2000-11-29 Smithkline Beecham Biolog Novel compounds
NZ540544A (en) 2000-10-27 2007-08-31 Inst Genomic Research Nucleic acids and proteins from streptococcus groups A & B
EP2339035A1 (en) 2000-12-07 2011-06-29 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
US7306806B2 (en) 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
CA2462946C (en) * 2001-01-26 2014-04-29 Jeffrey A. Lyon Recombinant p. falciparum merozoite protein-142 vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
CN1931365A (zh) 2001-06-29 2007-03-21 希龙公司 Hcv e1e2疫苗组合物
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
JP2005535308A (ja) 2002-06-13 2005-11-24 カイロン コーポレイション Ｈｍｌ−２ポリペプチド発現用ベクター
US7528223B2 (en) 2002-07-24 2009-05-05 Intercell Ag Antigens encoded by alternative reading frames from pathogenic viruses
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
JP2006504687A (ja) 2002-09-13 2006-02-09 インターツェル・アクチェンゲゼルシャフト Ｃ型肝炎ウイルスペプチドの単離方法
NZ562998A (en) 2002-10-11 2008-05-30 Novartis Vaccines & Diagnostic Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
CA2506318C (en) 2002-11-15 2011-07-12 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
CA2511512C (en) * 2002-12-27 2013-10-29 Chiron Corporation Immunogenic compositions containing phospholipid
KR100692203B1 (ko) * 2003-01-23 2007-03-09 제일모직주식회사 도광판, 이의 제조 방법, 이를 이용한 백라이트 어셈블리및 이를 이용한 액정표시장치
PT2172213E (pt) 2003-01-30 2013-06-03 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
CA2517673C (en) 2003-03-24 2013-08-13 Intercell Ag Improved vaccines for preventing viral infection
EP1608401A1 (en) * 2003-03-24 2005-12-28 Intercell AG Use of alum and a th1 immune response inducing adjuvant for enhancing immune respones
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
FR2854803B1 (fr) * 2003-05-16 2005-06-24 Aventis Pasteur Composition vaccinale comprenant du phosphate de fer a titre d'adjuvent vaccinal.
ES2328697T5 (es) 2003-06-02 2017-07-25 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunogénicas basadas en micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
PT1648500E (pt) 2003-07-31 2014-10-10 Novartis Vaccines & Diagnostic Composições imunogénicas para estreptococos piogenes
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
EP1722815A1 (en) 2004-03-09 2006-11-22 Chiron Corporation Influenza virus vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
EP1740217B1 (en) 2004-04-30 2011-06-15 Novartis Vaccines and Diagnostics S.r.l. Meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
JP4896021B2 (ja) 2004-05-21 2012-03-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 呼吸器系病原体ワクチンのためのアルファウイルスベクター
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP2682126B1 (en) 2005-01-27 2016-11-23 Children's Hospital & Research Center at Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
KR20070110513A (ko) * 2005-02-16 2007-11-19 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 알루미늄 포스페이트 및 3ｄ－ｍｐｌ을 포함하는 보조약조성물
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
CN101180312A (zh) 2005-02-18 2008-05-14 诺华疫苗和诊断公司 来自尿路病原性大肠杆菌的免疫原
AP2745A (en) * 2005-08-02 2013-09-30 Novartis Vaccines & Diagnostic Reducing interference between oil-containing adjuvants and surfactant-containing antigens
EP1945247A1 (en) 2005-10-18 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
BRPI0618254A2 (pt) * 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido
NZ567981A (en) 2005-11-04 2011-10-28 Novartis Vaccines & Diagnostic Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US7527801B2 (en) 2005-11-22 2009-05-05 Novartis Vaccines And Diagnostics, Inc. Norovirus and Sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
PL2347775T3 (pl) 2005-12-13 2020-11-16 President And Fellows Of Harvard College Rusztowania do przeszczepiania komórek
AR058592A1 (es) 2005-12-22 2008-02-13 Glaxosmithkline Biolog Sa Vacuna
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP1976559B3 (en) 2006-01-27 2020-02-19 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
SG173336A1 (en) 2006-03-31 2011-08-29 Novartis Ag Combined mucosal and parenteral immunization against hiv
CN1864749B (zh) * 2006-04-12 2010-10-06 成都夸常医学工业有限公司 一种药物组合物及制备方法
US9839685B2 (en) * 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
WO2008001224A2 (en) 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
ES2536401T3 (es) 2006-09-11 2015-05-25 Novartis Ag Fabricación de vacunas contra virus de la gripe sin usar huevos
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) * 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AU2007354917B2 (en) 2006-09-26 2013-06-06 Access To Advanced Health Institute Vaccine composition containing synthetic adjuvant
AU2007330494B2 (en) 2006-12-06 2014-03-13 Seqirus UK Limited Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
WO2009000824A2 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
SI2185191T1 (sl) 2007-06-27 2012-12-31 Novartis Ag Cepiva proti influenci z majhnimi dodatki
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
AU2008293504B2 (en) 2007-08-27 2012-04-12 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
EP2535428B1 (en) 2007-10-01 2015-09-09 Longhorn Vaccines and Diagnostics, LLC Biological specimen collection and transport system and methods of use
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PL2235046T3 (pl) 2007-12-21 2012-12-31 Novartis Ag Zmutowane formy streptolizyny O
PT2222710T (pt) * 2007-12-24 2016-11-02 Glaxosmithkline Biologicals Sa Antigénios de rsv recombinantes
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
ES2535101T3 (es) 2008-03-18 2015-05-05 Novartis Ag Mejoras en la preparación de antígenos en vacuna de virus de la gripe
CA2826508C (en) 2008-05-23 2016-07-19 The Regents Of The University Of Michigan Nanoemulsion vaccines
JP5726727B2 (ja) * 2008-05-26 2015-06-03 カディラ・ヘルスケア・リミテッド 麻疹−ヒトパピローマ混合ワクチン
WO2009147980A1 (ja) 2008-06-04 2009-12-10 財団法人化学及血清療法研究所 不活化日本脳炎ウイルス粒子をアジュバントとして使用する方法
MX2011000668A (es) * 2008-07-18 2011-07-29 Id Biomedical Corp Quebec Antigenos quimericos polipeptidicos del virus sincitial respiratorio.
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
KR101644221B1 (ko) 2008-12-09 2016-07-29 화이자 백신스 엘엘씨 ＩｇＥ ＣＨ３ 펩티드 백신
EA023662B1 (ru) 2009-02-10 2016-06-30 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
KR101738704B1 (ko) * 2009-02-17 2017-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 알루미늄-비함유 아주반트를 포함하는 불활성화 뎅기 바이러스 백신
NO2403507T3 (OSRAM) 2009-03-05 2018-07-21
ES2733084T3 (es) 2009-03-06 2019-11-27 Glaxosmithkline Biologicals Sa Antígenos de Chlamydia
AU2010238255B2 (en) 2009-04-14 2014-10-16 Novartis Ag Compositions for immunising against Staphylococcus aureus
EP2430040A1 (en) 2009-05-11 2012-03-21 Novartis AG Antigen purification process for pertactin antigen
JP5830015B2 (ja) * 2009-06-05 2015-12-09 インフェクシャス ディズィーズ リサーチ インスティチュート 合成グルコピラノシル脂質アジュバント
WO2010146414A1 (en) 2009-06-15 2010-12-23 National University Of Singapore Influenza vaccine, composition, and methods of use
CA2765511C (en) * 2009-06-16 2015-05-12 The Regents Of The University Of Michigan Nanoemulsion vaccines
SI2445526T1 (sl) 2009-06-24 2016-08-31 Glaxosmithkline Biologicals S.A. Rekombinantni RSV antigeni
CA2766205A1 (en) 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine comprising at least two paramyxovirus f protein antigens
CA2768172A1 (en) 2009-06-25 2010-12-29 Glaxosmithkline Biologicals S.A. Novel compositions
WO2011004263A2 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
JP5829210B2 (ja) 2009-07-15 2015-12-09 ノバルティス アーゲー Ｒｓｖｆタンパク質組成物およびそれを作製するための方法
CN102770443A (zh) 2009-07-16 2012-11-07 诺华有限公司 脱毒大肠杆菌免疫原
RU2518291C2 (ru) 2009-07-30 2014-06-10 Пфайзер Вэксинс ЭлЭлСи Антигенные tau-пептиды и их применения
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
CA2771863A1 (en) * 2009-08-26 2011-03-17 Selecta Biosciences, Inc. Compositions that induce t cell help
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
AU2010290931B2 (en) 2009-09-03 2014-02-06 Pfizer Vaccines Llc PCSK9 vaccine
MX338753B (es) 2009-09-30 2016-04-29 Novartis Ag Conjugacion de polisacaridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011077309A2 (en) 2009-12-22 2011-06-30 Pfizer Vaccines Llc Vaccine compositions
CN102869372B (zh) 2010-01-27 2016-01-20 葛兰素史密丝克莱恩生物有限公司 经修饰的结核抗原
EP4036104B1 (en) 2010-03-30 2024-02-21 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
US9597326B2 (en) 2010-04-13 2017-03-21 Glaxosmithkline Biologicals Sa Benzonapthyridine compositions and uses thereof
PL2575876T3 (pl) 2010-05-26 2018-07-31 Selecta Biosciences, Inc. Szczepionki poliwalentne z syntetycznymi nanonośnikami
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
WO2011148382A1 (en) 2010-05-28 2011-12-01 Biological E Limited An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
US8895017B2 (en) 2010-06-07 2014-11-25 Pfizer Inc. HER-2 peptides and vaccines
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
AU2011276328C1 (en) 2010-07-06 2016-01-21 Novartis Ag Norovirus derived immunogenic compositions and methods
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CN102441162B (zh) * 2010-10-04 2018-07-24 免疫产品美国股份有限公司 结核病的治疗和预防
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
SI2667892T1 (sl) 2011-01-26 2019-05-31 Glaxosmithkline Biologicals Sa Imunizacijski režim proti RSV
EP2680883B1 (en) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9 vaccine
JP5798356B2 (ja) * 2011-04-06 2015-10-21 一般財団法人化学及血清療法研究所 新規インフルエンザワクチン安定化剤
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
PT2707385T (pt) 2011-05-13 2017-12-19 Glaxosmithkline Biologicals Sa Antigénios de f de rsv pré-fusão
CA2843854A1 (en) * 2011-07-01 2013-01-10 The Regents Of The University Of California Herpes virus vaccine and methods of use
JP2014520807A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー 免疫原性組成物およびその使用
WO2013006838A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
FR2977800B1 (fr) 2011-07-13 2014-03-14 Sanofi Pasteur Composition vaccinale avec des nanoparticules d'hydroxyde d'aluminium
WO2013019658A2 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
WO2013028738A1 (en) 2011-08-22 2013-02-28 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
EP2753354A4 (en) 2011-09-09 2015-04-15 Nanobio Corp SUB-VACCINE IN NANOEMULSION FORM FOR RESPIRATORY SYNZYTIAL VIRUS
EP2755684A1 (en) 2011-09-12 2014-07-23 Jonathan Norden Weber Methods and compositions for raising an immune response to hiv
US20150044251A1 (en) 2011-12-23 2015-02-12 Novartis Ag Stable compositions for immunising against staphylococcus aureus
CA2863083C (en) 2012-01-26 2023-09-19 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
WO2013139744A1 (en) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
DK2838515T3 (da) * 2012-04-16 2020-02-24 Harvard College Mesoporøse siliciumdioxidsammensætninger til modulering af immunresponser
EP2659906A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
BR112014028476A2 (pt) 2012-05-16 2017-08-01 Immune Design Corp fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito
RU2014151567A (ru) 2012-05-22 2016-07-10 Новартис Аг Конъюгат менингококка серогруппы х
WO2014005958A1 (en) 2012-07-06 2014-01-09 Novartis Ag Immunogenic compositions and uses thereof
LT2890394T (lt) 2012-08-31 2019-07-25 Glaxosmithkline Biologicals Sa Stabilizuoti baltymai skirti imunizavimui nuo staphylococcus aureus
US20150203543A1 (en) 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
CN105307684A (zh) 2012-10-02 2016-02-03 葛兰素史密丝克莱恩生物有限公司 非直链糖缀合物
SG11201500979RA (en) 2012-10-03 2015-07-30 Glaxosmithkline Biolog Sa Immunogenic composition
CA2888293C (en) * 2012-10-19 2018-11-06 Hal Allergy Holding B.V. Compositions for immunotherapy
HUE036158T2 (hu) 2012-11-30 2018-06-28 Glaxosmithkline Biologicals Sa Pseudomonas antigének és antigén kombinációk
WO2014172637A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
AU2014385320B2 (en) 2013-05-15 2019-10-10 The Governors Of The University Of Alberta E1E2 HCV vaccines and methods of use
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3170344C (en) 2014-01-21 2023-08-29 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
WO2015144655A1 (en) 2014-03-26 2015-10-01 Glaxosmithkline Biologicals S.A. Immunising against staphylococcus aureus
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
EP3172224B1 (en) 2014-07-23 2022-06-29 Children's Hospital & Research Center at Oakland Factor h binding protein variants and methods of use thereof
IL252915B2 (en) 2015-01-15 2024-04-01 Pfizer Immunogenic compositions for use in pneumococcal vaccines
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
US10576131B2 (en) 2015-06-03 2020-03-03 Affiris Ag IL-23-p19 vaccines
AU2016289497A1 (en) 2015-07-07 2017-12-07 Affiris Ag Vaccines for the treatment and prevention of IgE mediated diseases
TWI720448B (zh) 2015-07-21 2021-03-01 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
EP4480544A3 (en) 2015-08-25 2025-03-26 Babita Agrawal Immunomodulatory compositions andmethods of use thereof
CA3000313A1 (en) 2015-10-08 2017-04-13 The Governors Of The University Of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN115531609A (zh) 2016-02-06 2022-12-30 哈佛学院校长同事会 重塑造血巢以重建免疫
DK3484448T3 (da) 2016-07-13 2025-06-10 Harvard College Antigenpræsenterende cellemimetiske stilladser og fremgangsmåder til fremstilling og brug af disse
IL264557B2 (en) 2016-08-02 2024-01-01 Harvard College Biological agents for regulating immune responses
BE1024774B1 (fr) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions et procedes de traitement
EP3545972A4 (en) 2016-11-25 2020-05-13 Mogam Institute For Biomedical Research VARICELLA AND ZONA VIRUS VACCINE
WO2018097642A1 (ko) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
KR102459629B1 (ko) 2017-01-20 2022-10-28 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
CN107537035A (zh) * 2017-08-30 2018-01-05 北京恩元华生物科技有限公司 复合佐剂及含复合佐剂的狂犬疫苗及其制备方法和应用
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
TW201946650A (zh) 2018-03-12 2019-12-16 美商詹森藥物公司 針對腹內感染之疫苗
MX2020013553A (es) 2018-06-12 2021-02-26 Glaxosmithkline Biologicals Sa Polinucleotidos y polipeptidos de adenovirus.
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
IL282753B2 (en) 2018-11-06 2025-04-01 Glaxosmithkline Biologicals Sa Immunogenic compounds
JP7585203B2 (ja) 2018-12-12 2024-11-18 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
WO2020128012A1 (en) 2018-12-21 2020-06-25 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220339281A1 (en) 2019-03-05 2022-10-27 GalxoSmithKline Biologicals SA Hepatitis b immunisation regimen and compositions
TWI751513B (zh) 2019-03-18 2022-01-01 美商詹森藥物公司 E. coli O-抗原多醣生物結合物、其製備方法及其使用方法
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN112138155B (zh) * 2019-06-28 2022-04-12 怡道生物科技(苏州)有限公司 一种复合佐剂系统及制备该佐剂的方法
JP2022549270A (ja) 2019-09-23 2022-11-24 プレジデント アンド フェローズ オブ ハーバード カレッジ バイオマテリアルベースの無抗原ワクチンおよびその使用
WO2021067785A1 (en) 2019-10-02 2021-04-08 Janssen Vaccines & Prevention B.V Staphylococcus peptides and methods of use
KR20220092572A (ko) 2019-11-01 2022-07-01 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그 방법
KR20220128372A (ko) 2020-01-16 2022-09-20 얀센 파마슈티칼즈, 인코포레이티드 Fimh 돌연변이체, 이를 갖는 조성물 및 이의 용도
CA3165957A1 (en) 2020-01-24 2021-07-29 Thomas K. EQUELS Methods, compositions, and vaccines for treating a virus infection
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
KR20220144393A (ko) 2020-02-21 2022-10-26 화이자 인코포레이티드 당류의 정제
JP2023514697A (ja) 2020-02-23 2023-04-07 ファイザー・インク 大腸菌組成物およびその方法
JP2023514825A (ja) 2020-02-26 2023-04-11 ヴェルシテック リミテッド コロナウイルス感染症に対するｐｄ－１ベースのワクチン
CN111920946B (zh) * 2020-08-07 2021-05-28 合肥诺为尔基因科技服务有限公司 环二核苷酸修饰铝纳米粒疫苗佐剂-传递系统及基于其的SARS-CoV-2亚单位疫苗
IL301248B2 (en) 2020-09-17 2024-04-01 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof
US12403189B2 (en) 2020-10-20 2025-09-02 Longhorn Vaccines And Diagnostics, Llc Immunogenic antigens
TW202227467A (zh) 2020-10-27 2022-07-16 美商輝瑞大藥廠 大腸桿菌組合物及其方法
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
CN116744965A (zh) 2020-11-04 2023-09-12 辉瑞大药厂 用于肺炎球菌疫苗的免疫原性组合物
JP7804673B2 (ja) 2020-11-10 2026-01-22 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
AU2022207740B2 (en) 2021-01-12 2024-06-06 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof
CA3210363A1 (en) 2021-02-11 2022-08-18 Glaxosmithkline Biologicals Sa Hpv vaccine manufacture
IT202100003470A1 (it) 2021-02-16 2022-08-16 Fond Toscana Life Sciences Vaccines against sars-cov-2
JP2024507828A (ja) 2021-02-19 2024-02-21 サノフィ パスツール インコーポレイテッド Ｂ群髄膜炎菌組換えワクチン
CN115120713A (zh) * 2021-03-25 2022-09-30 四川大学 氢氧化铝-CpG寡核苷酸-多肽复合佐剂、疫苗及制备方法和用途
EP4313135A1 (en) 2021-04-01 2024-02-07 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates
EP4333868A1 (en) 2021-05-04 2024-03-13 King Abdullah University Of Science And Technology Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
MX2023013434A (es) 2021-05-28 2023-12-12 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20240149460A (ko) 2021-11-18 2024-10-14 매트리박스, 인크. 면역원성 융합 단백질 조성물 및 이의 사용 방법
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
US20250163484A1 (en) 2022-02-25 2025-05-22 Pfizer Inc. Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
KR20250008122A (ko) 2022-05-11 2025-01-14 화이자 인코포레이티드 보존제를 갖는 백신 제형의 제조 방법
AU2023309805A1 (en) 2022-07-22 2025-01-23 Centre Hospitalier Universitaire De Lille Use of bordetella strains for the treatment of chronic obstructive pulmonary disease
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
IL321062A (en) 2022-11-22 2025-07-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4626405A1 (en) 2022-12-01 2025-10-08 Pfizer Inc. Pneumococcal conjugate vaccine formulations
JP2026501211A (ja) 2022-12-19 2026-01-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｂ型肝炎組成物
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121263203A (zh) 2023-05-19 2026-01-02 葛兰素史克生物有限公司 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法
WO2025028658A1 (ja) * 2023-08-03 2025-02-06 国立大学法人東京農工大学 免疫増強剤及び免疫増強方法並びにタンパク質の凝集体及び／又は会合体の製造方法
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186660A1 (en) 2024-03-05 2025-09-12 Fondazione Toscana Life Sciences Mutated spike proteins as vaccines against sars-cov-2
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2861538D1 (en) 1977-12-20 1982-02-25 Secr Defence Brit Liquid crystal displays
DE2837342A1 (de) 1978-08-26 1980-03-06 Henkel Kgaa Verfahren zur herstellung von hefeautolysat
EP0111984B1 (en) 1982-12-23 1989-08-02 THE PROCTER & GAMBLE COMPANY Ethoxylated amine polymers having clay soil removal/anti-redeposition properties useful in detergent compositions
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
ZA88488B (en) 1987-01-30 1988-10-26 Smith Kline Rit Hepatitis b virus surface antigens and hybrid antigens containing them
WO1988009797A1 (en) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Autocrine motility factors in cancer diagnosis and management
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
ATE105858T1 (de) 1987-07-17 1994-06-15 Rhein Biotech Ges Fuer Biotech Dna-moleküle, die für fmdh-kontrollabschnitte und strukturgene für ein protein mit fmdh-aktivität kodieren, sowie deren anwendung.
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
DE3834729A1 (de) * 1988-10-12 1990-04-19 Behringwerke Ag Verwendung von zink-oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
DK0414374T3 (da) 1989-07-25 1998-03-09 Smithkline Beecham Biolog Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
CA2067003A1 (en) 1991-04-29 1992-10-30 Peter J. Kniskern Hbsag escape mutant vaccine
WO1993010152A1 (en) 1991-11-16 1993-05-27 Smithkline Beecham Biologicals S.A. HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
SK280702B6 (sk) 1992-05-23 2000-06-12 Smithkline Beecham Biologicals S. A. Kombinovaný očkovací prostriedok obsahujúci povrch
DE122007000101I1 (de) * 1992-06-25 2008-03-27 Papillomavirus vakzine
KR100278157B1 (ko) * 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
SK117395A3 (en) 1993-03-23 1996-11-06 Smithkline Beecham Biolog Vaccine composition and manufacturing process thereof
WO1994027636A1 (en) * 1993-05-25 1994-12-08 American Cyanamid Company Adjuvants for vaccines against respiratory syncytial virus
DE4322107A1 (de) 1993-07-02 1995-01-12 Siemens Ag Einrichtung zum Auffangen und Kühlen von Kernschmelze
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU693203B2 (en) 1994-05-16 1998-06-25 Merck Sharp & Dohme Corp. Papillomavirus vaccines
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
DE122007000092I1 (de) 1994-10-07 2008-03-27 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
WO1996026277A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US6488934B1 (en) * 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
KR0184779B1 (ko) * 1995-04-13 1999-04-01 성재갑 퀼라야 사포나리아 몰리나로부터 분리정제된 사포닌 변이체, 이의 분리정제 방법 및 이를 함유하는 백신 제형
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US6251405B1 (en) 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
AP812A (en) * 1995-06-23 2000-02-24 Smithkline Biologicals S A A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate.
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5733011A (en) * 1997-02-06 1998-03-31 Richard A. Young Multiple position tool caddy seat
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
ATE339223T1 (de) 1998-03-09 2006-10-15 Glaxosmithkline Biolog Sa Kombinierte impfstoffzusammensetzungen
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9806666D0 (en) 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
SK2232001A3 (en) * 1998-08-14 2001-08-06 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
GB9819898D0 (en) 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
IL142395A0 (en) 1998-10-16 2002-03-10 Smithkline Beecham Biolog Adjuvant systems and vaccines
AUPP765398A0 (en) * 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
WO2001011027A1 (es) 1999-08-06 2001-02-15 Glaxo Wellcome, S.A. Nueva proteina
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0110431D0 (en) 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
KR101361769B1 (ko) * 2002-12-20 2014-02-10 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｐｖ-16 ｌ1 ｖｌｐ 및 ｈｐｖ-18 ｌ1 ｖｌｐ 백신
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
JP2007505128A (ja) 2003-09-10 2007-03-08 エス−セル バイオサイエンシズ、インク． 造血を高める方法
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52

Also Published As

Publication number Publication date
CY1106596T1 (el) 2010-07-28
NO336250B1 (no) 2015-06-29
TW586936B (en) 2004-05-11
CN1330553A (zh) 2002-01-09
NL300311I1 (nl) 2008-02-01
HUP0203091A1 (hu) 2002-12-28
HK1038695A1 (en) 2002-03-28
HUP0203091A3 (en) 2008-04-28
WO2000023105A2 (en) 2000-04-27
DE122007000087I1 (de) 2008-03-27
NO20011801D0 (no) 2001-04-09
BR9915545A (pt) 2001-08-14
CO5210894A1 (es) 2002-10-30
EP1797896A1 (en) 2007-06-20
LU91389I9 (OSRAM) 2019-01-02
JP2012121916A (ja) 2012-06-28
AR020836A1 (es) 2002-05-29
AU1151800A (en) 2000-05-08
HU228473B1 (en) 2013-03-28
KR20010075638A (ko) 2001-08-09
CN100406060C (zh) 2008-07-30
JP5667107B2 (ja) 2015-02-12
BR9915545B1 (pt) 2013-08-06
EP1588714A2 (en) 2005-10-26
EP1126876B1 (en) 2007-03-21
EP1666060A1 (en) 2006-06-07
JP2007262097A (ja) 2007-10-11
PL201482B1 (pl) 2009-04-30
CN101926993B (zh) 2013-12-04
AU750587B2 (en) 2002-07-25
EP2266604A3 (en) 2011-05-11
DE69935606D1 (de) 2007-05-03
PL348121A1 (en) 2002-05-06
CA2347099A1 (en) 2000-04-27
MY124689A (en) 2006-06-30
CA2773698A1 (en) 2000-04-27
DE69935606T9 (de) 2021-03-11
US8628784B2 (en) 2014-01-14
CY2007032I1 (el) 2009-11-04
ATE357252T1 (de) 2007-04-15
NL300311I2 (nl) 2008-04-01
SI1126876T1 (sl) 2007-08-31
US20080226672A1 (en) 2008-09-18
PT1126876E (pt) 2007-04-30
US9623114B2 (en) 2017-04-18
CA2347099C (en) 2014-08-05
CZ20011341A3 (cs) 2001-09-12
US20140105992A1 (en) 2014-04-17
EP1126876A2 (en) 2001-08-29
HUS1300050I1 (hu) 2019-06-28
US7357936B1 (en) 2008-04-15
CZ301212B6 (cs) 2009-12-09
CN100558401C (zh) 2009-11-11
TR200101055T2 (tr) 2001-09-21
EP2266604A2 (en) 2010-12-29
FR07C0064I1 (fr) 2008-02-01
JP2003519084A (ja) 2003-06-17
DE69935606T2 (de) 2007-11-29
IL142395A0 (en) 2002-03-10
JP5563189B2 (ja) 2014-07-30
LU91389I2 (fr) 2008-02-14
CY2007032I2 (el) 2009-11-04
DK1126876T3 (da) 2007-07-02
CN101926993A (zh) 2010-12-29
IL142395A (en) 2006-08-01
HK1038695B (en) 2007-09-14
BRPI9915545B8 (pt) 2021-05-25
CN1572324A (zh) 2005-02-02
ES2284287T3 (es) 2007-11-01
KR100629028B1 (ko) 2006-09-26
NO20011801L (no) 2001-05-30
WO2000023105A3 (en) 2000-08-03
CA2773698C (en) 2015-05-19

Similar Documents

Publication Publication Date Title
NZ511113A (en) Adjuvant systems containing an immunostimulant absorbed on to a metal salt particle and vaccines thereof
MY134811A (en) A vaccine composition comprising an antigen, a saponin and a sterol
NZ334734A (en) Vaccine composition comprising alum, a saponin fraction (QS21), a sterol (cholesterol), SUV (liposome forming) and MPL (3-de-O-acylated monophosphoryl lipid A)
UA40596C2 (uk) Композиція вакцини та спосіб її одержання
NZ527560A (en) Combined vaccine composition comprising HPV antigens with aluminium hydroxide and 3D MPL adjuvant
MY133981A (en) Vaccine composition
NZ596870A (en) Vaccine compositions comprising a saponin adjuvant
MY109278A (en) Vaccines
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
EP2368573A3 (en) Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
AU3526995A (en) Vaccine compositions
UY24654A1 (es) Composición de vacuna contra la malaria
IL139601A0 (en) Compositions and methods of modulating an immune response to an antigen
NZ238042A (en) Vaccines containing polypeptide immunogen with long chain alkyl compound
WO2001015727A3 (en) Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
IL159519A0 (en) Vaccine composition comprising at least two valences, one enhanced with adjuvant and not the other
AU2471201A (en) Plant lectins as mucosal adjuvants
AU636907B2 (en) Bovine ephemeral fever and antigens and vaccines derived therefrom
AR012896A1 (es) Polipeptido flge de helicobacter pylori, composicion de vacuna, uso de dicho polipeptido para la fabricacion de composiciones, metodo de diagnostico invitro, y kit de diagnostico para la deteccion de la infeccion por helicobacter pylori
SU1412586A1 (ru) Устройство для получения и вывода частиц
Nemeth Potency-determination of bacterial antigens adjuvanted by liposomes.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired